TDC
RPRX

Thompson Davis & Co’s Repros Therapeutics Inc. RPRX Stock Holding History

Thompson Davis & Co’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-250
Closed -$2K – 1385
2014
Q4 		$2K Buy
250
+125
+100% +$1.07K ﹤0.01% 1136
2014
Q3 		$1K Buy
+125
New +$1.85K ﹤0.01% 1129

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Thompson Davis & Co's RPRX Position: Q1 2015 in Review

Thompson Davis & Co sold out of Repros Therapeutics Inc. (RPRX) in Q1 2015, closing a stake of 250 shares — an estimated $2K sold.

Thompson Davis & Co first reported a position in RPRX in Q3 2014 and held it in 2 quarters. The position peaked at $2K in Q4 2014. 72 funds tracked by Wall St. Rank hold RPRX as of Q1 2015.

  • Thompson Davis & Co reported no remaining Repros Therapeutics Inc. position as of Q1 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Repros Therapeutics Inc. shares in Q1 2015, an estimated $2K.
  • Thompson Davis & Co first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 2 quarters.
  • Thompson Davis & Co's Repros Therapeutics Inc. position peaked at $2K in Q4 2014.
  • 72 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.